MTOR and COVID-19: Of the 11 patients infected, 7 (63.6%) had COVID-19; in particular, six had a mild form of the disease, while 1 had a moderate form of the disease (OR for moderate/severe form vs. mild:0.8, 95, CI: (0.21–0.92) mTOR inhibitors recipients vs. other regimens; p = 0.041) (Tables 2, 5, 6).